A week ago today, the Therapeutic Goods Administration approved AstraZeneca’s submission to amend the brand name of its COVID-19 vaccine to ‘Vaxzevria’.

The change ensured that the brand name of the Australian-produced vaccine would match the name of the same vaccine in the European Union and other overseas jurisdictions, clearing confusion between the two names.

After the change was announced, some AstraZeneca vaccine recipients expressed concern that their vaccination would not be recognised in Europe, as they had received the vaccine before the name change. The brand name of the vaccine had been listed as ‘COVID-19 Vaccine AstraZeneca’ on immunisation history statements, with no mention of the Vaxzevria brand.

Australia Zone can confirm, however, that immunisation history statements have now been updated to list the vaccine’s brand name as ‘AstraZeneca Vaxzevria’ for those who have received it, even if the immunisation occurred prior to the name change.

Vaccine branded under the previous name will continue to be rolled out in Australia, with Vaxzevria-branded vaccine to enter supply by the end of the year. Regardless of which brand a person receives, the new Vaxzevria brand name will be listed on that person’s immunisation history, as there is no other difference between the AstraZeneca and Vaxzevria vaccines.

In the last 24 hours there were 335,420 vaccine doses administered in Australia, most of which were of the Pfizer/Comirnaty brand. Today’s vaccination figure trumps the previous daily record of 310,524 doses.